Adapt Or Die: Sanofi CSO On R&D Challenges Within Unstable Industry
Executive Summary
Sanofi's chief scientific officer Gary Nabel, who joined the company in 2012 from the NIH, discusses R&D challenges for Sanofi and the wider pharma industry, and highlights the company's biggest drug development achievements and toughest moments over the last few years.
You may also be interested in...
Flu Vax Giant Sanofi Defends Corner With $650m Protein Sciences Buy
In agreeing a $650m+ deal to acquire privately owned Protein Sciences, Sanofi is defending its market dominance in influenza vaccinations by adding an approved non-egg based product. The purchase may also help it defend its position in the section of the market targeting elderly patients, since its current trivalent offering is threatened by a rival quadrivalent product from Seqirus.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.